Clinical Trials

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05453903 2026-04-13

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Leukemia, Myeloid, Acute

NCT06788756 2026-04-13

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Phase 2/3 Recruiting

312 enrolled

Leukemia, Myeloid, Acute

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Recruiting

1,300 enrolled

Phase 1/2 Active not recruiting

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

65 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06578247 2026-03-31

QuANTUM-WILD

Phase 3 Recruiting

700 enrolled

Phase 2 Active not recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Phase 2/3 Not yet recruiting

216 enrolled

Leukemia, Myeloid, Acute

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

MyeloidOther hematologic neoplasmPlasma cell

21 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03182244 2026-02-06

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3 Active not recruiting

276 enrolled 41 charts

Leukemia, Myeloid, Acute

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

167 enrolled

Leukemia, Myeloid, Acute

NCT04240002 2026-01-05

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

9 enrolled 21 charts

Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 4 FDA

Leukemia, Myeloid, Acute

NCT06533761 2025-10-22

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

125 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT04229979 2025-10-01

REGAL

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 3 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT05319587 2025-09-30

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

22 enrolled

Leukemia, Myeloid, Acute

NCT05712278 2025-09-12

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Terminated

7 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02310321 2025-09-02

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

97 enrolled 30 charts

Leukemia, Myeloid, Acute

NCT04891757 2025-07-10

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

144 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

336 enrolled 48 charts 2 FDA

LymphoidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05521087 2025-06-22

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1 Withdrawn

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02632708 2025-04-11

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

153 enrolled

Leukemia, Myeloid, Acute

NCT05241093 2025-04-10

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 2 Recruiting

18 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT05586074 2025-04-09

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Phase 3 Recruiting

324 enrolled

Leukemia, Myeloid, Acute

NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

7 enrolled 16 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02038777 2025-02-26

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

48 enrolled 85 charts

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Leukemia, Myeloid, Acute

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

61 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

CNSLymphoidOther hematologic neoplasm

38 enrolled 34 charts

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

122 enrolled 29 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02236013 2024-11-05

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

80 enrolled

Leukemia, Myeloid, Acute

NCT04275518 2024-10-15

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01838395 2024-09-19

Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

Phase 2 Completed

42 enrolled 19 charts

Leukemia, Myeloid, Acute

NCT02668653 2024-08-06

QuANTUM-First

539 enrolled 20 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02400281 2024-07-03

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

28 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT04113616 2024-03-22

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

70 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03379727 2024-02-29

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

301 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT04956042 2024-02-12

Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia

18 enrolled

Leukemia, Myeloid, Acute

NCT05020665 2024-01-10

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Phase 3 Terminated

15 enrolled 11 charts

Phase 3 Not yet recruiting

Leukemia, Myeloid, Acute

NCT06182592 2023-12-28

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

120 enrolled

Neoplasm Metastasis, Leukemia, Myeloid, Acute

NCT02626338 2023-12-20

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

16 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT02520011 2023-11-15

Alvocidib Biomarker-driven Phase 2 AML Study

Phase 2 Terminated

104 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT03298984 2023-11-15

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

32 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT03969420 2023-11-09

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Phase 2 Terminated

11 enrolled 10 charts

Recurrence, Leukemia, Myeloid, Acute

NCT02957032 2023-10-10

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1 Terminated

30 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT00804856 2023-10-03

Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Phase 2 Completed

180 enrolled 44 charts

Leukemia, Myeloid, Acute

NCT05456269 2023-10-03

BISECT

Phase 1 Withdrawn